Palisade Bio Inc. (PALI)
0.66
-0.01 (-1.46%)
At close: Apr 02, 2025, 3:47 PM
0.67
1.18%
After-hours: Apr 02, 2025, 07:50 PM EDT
Company Description
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract.
Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery.
The company was founded in 2005 and is headquartered in Carlsbad, California.
Palisade Bio Inc.

Country | United States |
IPO Date | Mar 30, 2007 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 8 |
CEO | J. D. Finley |
Contact Details
Address: 5800 Armada Drive Carlsbad, California United States | |
Website | https://www.palisadebio.com |
Stock Details
Ticker Symbol | PALI |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001357459 |
CUSIP Number | 696389105 |
ISIN Number | US6963892046 |
Employer ID | 52-2007292 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
J. D. Finley | Chief Executive Officer, Chief Financial Officer & Director |
Dr. Mitchell Lawrence Jones M.D., Ph.D. | Chief Operating Officer & Chief Medical Officer |
Dr. Joerg Heyer Ph.D. | Head of Translational Science & Medicine |
Ryker Willie | Senior Vice President of Finance & Corporate Controller |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 24, 2025 | 10-K | Annual Report |
Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Feb 13, 2025 | 4 | Filing |
Feb 13, 2025 | 4 | Filing |
Dec 17, 2024 | 424B3 | Filing |
Dec 17, 2024 | 424B3 | Filing |
Dec 17, 2024 | 424B3 | Filing |
Dec 16, 2024 | 8-K | Current Report |
Dec 13, 2024 | 424B5 | Filing |
Dec 13, 2024 | POS AM | Filing |